MoFo News Item

Morrison & Foerster Secures $41.8M Jury Award for Client Seagen Inc.

13 Apr 2022

In a jury trial in Marshall, Texas that concluded on Friday, April 8, Morrison & Foerster secured a complete victory for its client Seagen Inc. in patent litigation involving Seagen’s pioneering antibody-drug conjugate technology. 

The jury in the U.S. District Court for the Eastern District of Texas found that Daiichi Sankyo willfully infringed Seagen’s patent (U.S. Patent No. 10,808,039) through sales of its Enhertu cancer treatment and held the patent not invalid. The jury awarded $41.8 million in damages—the entire amount Seagen requested. 

The Morrison & Foerster trial team representing Seagen included Michael Jacobs, Matthew Chivvis, Bryan Wilson, Matthew Kreeger, Jayson Cohen, Sumaiya Sharmeen, Karl Johnston, Chris Han and Evelyn Chang.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.